Generali Asset Management’s United Therapeutics UTHR Stock Holding History

Generali Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.99M	Buy	3,358 +384	+13%	+$191K	0.04%	295
2025 Q4	$1.45M	Sell	2,974 -1,654	-36%	-$770K	0.03%	360
2025 Q3	$1.94M	Sell	4,628 -1,587	-26%	-$534K	0.04%	316
2025 Q2	$1.79M	Sell	6,215 -1,486	-19%	-$444K	0.04%	335
2025 Q1	$2.37M	Sell	7,701 -823	-10%	-$282K	0.06%	283
2024 Q4	$3.01M	Buy	+8,524	New	+$3.13M	0.08%	250

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Generali Asset Management's UTHR Position: Q1 2026 in Review

Generali Asset Management increased its United Therapeutics (UTHR) stake by 13% in Q1 2026, buying an estimated $191K and bringing the position to 3,358 shares worth $1.99M. The position accounts for 0.04% of the portfolio, ranked #295.

Generali Asset Management first reported a position in UTHR in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.01M in Q4 2024. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

Generali Asset Management held 3,358 shares of United Therapeutics worth $1.99M as of Q1 2026.
Generali Asset Management bought 384 United Therapeutics shares in Q1 2026, an estimated $191K.
United Therapeutics made up 0.04% of Generali Asset Management's portfolio in Q1 2026, its #295 holding.
Generali Asset Management first reported a position in United Therapeutics in Q4 2024 and has held it in 6 quarters since.
Generali Asset Management's United Therapeutics position peaked at $3.01M in Q4 2024.
850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Generali Asset Management's 13F filing for Q1 2026, filed 5 May 2026.